Imaging biomarkers for Parkinson s disease

Similar documents
Update on functional brain imaging in Movement Disorders

Learnings from Parkinson s disease: Critical role of Biomarkers in successful drug development

Transcranial sonography in movement disorders

Corporate Medical Policy

PPMI Imaging Core Update

Biomedical Technology Research Center 2011 Workshop San Francisco, CA

FDG-PET e parkinsonismi

Pietro Cortelli. IRCCS Istituto delle Scienze Neurologiche di Bologna DIBINEM, Alma Mater Studiorum - Università di Bologna

Change the size of any window by dragging the lower left corner. Use controls

Il ruolo di nuove tecniche di imaging per la diagnosi precoce di demenza

Dopamine Transporter Imaging With Single-Photon Emission Computed. Tomography

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

DOWNLOAD PDF DOPAMINERGIC IMAGING IN PARKINSONS DISEASE : SPECT CHRISTOPH SCHERFLER AND WERNER POEWE

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

PET ligands and metabolic brain imaging Prof. Karl Herholz

212 Index C-SB-13,

Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge

Dopamine Transporter Imaging With Single-Photon Emission Computed. Tomography

Dementia and Healthy Ageing : is the pathology any different?

L ecografia cerebrale: accuratezza diagnostica Dr Patrizio Prati Neurologia CIDIMU Torino

Form D1: Clinician Diagnosis

Visualization and Quantification of the Striato pallidonigral Fibers in Parkinson's Disease Using Diffusion Tensor Imaging

Parkinson e decadimento cognitivo. Stelvio Sestini

Early Clinical Features of Parkinson s Disease and Related Disorders. Dr. Alastair Noyce

Differential Diagnosis of Hypokinetic Movement Disorders

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

Neuro degenerative PET image from FDG, amyloid to Tau

La neurosonologia. Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative. Nelle patologie degenerative e vascolari cerebrali

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Dopamine Transporter Imaging with Single Photon Emission Computed Tomography

Basal ganglia motor circuit

Atypical parkinsonism

Lecture 42: Final Review. Martin Wessendorf, Ph.D.

! slow, progressive, permanent loss of neurologic function.

Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation

Clinical Features and Treatment of Parkinson s Disease

Reduction of Neuromelanin-Positive Nigral Volume in Patients with MSA, PSP and CBD

PARKINSON S PROGRESSION MARKERS INITIATIVE. PPMI 2018 Annual Investigators Meeting PPMI Data Blitz

Brain imaging for the diagnosis of people with suspected dementia

Draft agreed by Scientific Advice Working Party 26 October Adopted by CHMP for release for consultation 09 November

III./3.1. Movement disorders with akinetic rigid symptoms

Imaging biomarkers in Parkinson s disease and Parkinsonian syndromes: current and emerging concepts

Evaluating the roles of the basal ganglia and the cerebellum in time perception

brain MRI for neuropsychiatrists: what do you need to know

ORIGINAL CONTRIBUTION. Transcranial Brain Sonography Findings in Discriminating Between Parkinsonism and Idiopathic Parkinson Disease

FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE

Parkinson s Disease Update

Parkinsonism in corticobasal syndrome may not be primarily due to presynaptic dopaminergic deficiency

Views and Reviews. [ 123 I]FP-CIT (DaTscan) SPECT Brain Imaging in Patients with Suspected Parkinsonian Syndromes ABSTRACT

MINERVA MEDICA COPYRIGHT

T he main symptoms of idiopathic Parkinson s disease

Evaluations & CE. With Support From. Featured Speaker 1/20/2016. Conflict of Interest & Disclosure Statements

An update on advances in magnetic resonance imaging of multiple system atrophy

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota

SPECT and PET Imaging: DaT Scan, Cerebral Blood Flow and Epilepsy

Role of Neuroimaging on Differentiation of Parkinson s Disease and Its Related Diseases

Diagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16

CSF Aβ1-42 predicts cognitive impairment in de novo PD patients

Non-Genetic Ataxia Susan L. Perlman, M.D. Clinical Professor of Neurology David Geffen School of Medicine at UCLA Director, Ataxia Clinic

ARTICLE The scientific and clinical basis for the treatment of Parkinson disease (2009)

Role of Magnetic Resonance Imaging in the Diagnosis of Adult Onset Movement Disorders

Dopamine Transporter Imaging With Single-Photon Emission Computed Tomography

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

A Parkinson s Disease and related disorders

FTD basics! Etienne de Villers-Sidani, MD!

The dopamine transporter is a sodium chloride dependent. The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 2

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

Using Resting-State Functional Connectivity of the Basal Ganglia as a Biomarker for Symptoms of Parkinson's Disease

Synaptic changes in dementia: links to cognition and behaviour

Dementia syndrome. Manifestation DISORDERS & DEMENTIA. Reasons of demencia

PPMI Data Overview. Christopher S. Coffey The University of Iowa. PPMI Investigators Meeting May 13-14, 2015 New York, NY

Facility IBA 18/9 Cyclotron Accelerates p and d. Facility GMP Grade Clean Room Automated Dispenser Synthera Rig FDG 07/11/2014

The Parkinson s You Can t See

Parkinson s UK Brain Bank

Evaluation of Parkinson s Patients and Primary Care Providers

On the nature of Rhythm, Time & Memory. Sundeep Teki Auditory Group Wellcome Trust Centre for Neuroimaging University College London

Use of Multimodal Neuroimaging Techniques to Examine Age, Sex, and Alcohol-Related Changes in Brain Structure Through Adolescence and Young Adulthood

Utilizing the items from the MDS-UPDRS score to increase drug effect detection power in de novo idiopathic Parkinson's disease patients

Structural and Functional Imaging in Parkinsonian Syndromes 1

Please note that these comments and the identity of the sender will be published unless a specific justified objection is received.

Hypokinetic Movement Disorders

United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline

Differential Diagnosis

review of existing studies on ASL in dementia Marion Smits, MD PhD

Dementia: A Comprehensive Update Neuroimaging, CSF, and genetic biomarkers in dementia

This is a free sample of content from Parkinson's Disease. Click here for more information or to buy the book.

DOWNLOAD OR READ : MIDBRAIN NEUROPATHOLOGY IN IDIOPATHIC PARKINSONS DISEASE AND DIFFUSE LEWY BODY DISEASE PDF EBOOK EPUB MOBI

Role of Biomarkers and Clinical Markers in patient selection and monitoring in PD. Ken Marek Institute for Neurodegenerative Disorders Feb 22, 2018

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit

Review Article Positron emission tomography neuroimaging in Parkinson s disease

DEMENS MED LEWYLEGEMER OG PARKINSON DEMENS

The Latest Research in Parkinson s Disease. Lawrence Elmer, MD, PhD Professor, Dept. of Neurology University of Toledo

How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci.

Metabolic network expression in parkinsonism: Clinical and dopaminergic correlations

LRRK2 AS THERAPEUTIC TARGET. Jan Egebjerg

NIH Public Access Author Manuscript Semin Neurol. Author manuscript; available in PMC 2014 November 14.

The current diagnosis of idiopathic Parkinson s disease

Transcription:

3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 6 MDS-ES/EAN: Neuroimaging in movement disorders - Level 2 Imaging biomarkers for Parkinson s disease David J. Brooks London, United Kingdom Email: david.brooks@imperial.ac.uk

Imaging biomarkers for Parkinson s disease David J Brooks α-synuclein aggregation Shah 2014 Conflict of interest: David Brooks has worked as a Consultant for GE Healthcare who own the licence for DatSCAN 1

BF227 binding to Lewy bodies and GCIs BF227 fluorescence α-syn immunostaining Kikuchi 2010 Multiple System Atrophy Kikuchi 2010 Alzheimer s disease 2

Imaging nigrosome 1 T2-weighted iron sensitive SWI 7 tesla MRI Blazejewska 2013 Imaging nigrosome 1 Susceptibility weighted imaging 3 tesla MRI Reiter 2015 3

Diffusion tensor imaging 3 tesla MRI Fractional anisotropy Cerebral peduncle Vaillancourt et al. Neurology 2009;72:1387 84 PPMI cohort DTI changes in de novo PD PPMI database Schuff et al. 2016 4

Free water is increased in Parkinson nigra Ofori 2015 Free water changes in PD, MSA and PSP Plancetta 2016 5

Free water pool progression in PD Bircui 2017 Magnetisation transfer imaging of neuromelanin Loss of substantia nigra signal in PD Langley 2015 6

Reduced melanin volumes in Parkinson s disease Langley 2015 Imaging melanin with 18 F-AV1451 PET Hansen et al. 2016 Controls PD 7

normal Transcranial Sonography in clinically uncertain PD ipd 60 cases had baseline TCS and were followed up for 12 months in a blinded prospective study Nigral hyperechogenicity had a sensitivity of 91%, a specificity of 82%, a positive predictive value of 93%, but a negative predictive value of 78% for detecting ipd. Gaenslen 2008 Imaging dopamine terminal function 18 F-FP-CIT 123 I-FP-CIT 18 F-DTBZ 11 C-DTBZ 18 F-DOPA DAT DAT VMAT2 VMAT2 DDC Normal PD 8

Striatal DAT vs nigral melanin FP-CIT Hansen 2016 AV1451 No correlation between striatal DAT binding and nigral melanin No correlation between disease duration and melanin DA imaging: diagnostic support Nigrostriatal dopaminergic deficiency No dopaminergic deficiency Idiopathic PD Multiple system atrophy Progressive supranuclear palsy Corticobasal degeneration Lewy body dementia Spinocerebellar ataxia SCA 2 Vascular parkinsonism Drug-induced parkinsonism Psychogenic parkinsonism Dopa responsive dystonia Essential tremor Dystonic tremor Vascular parkinsonism 9

Discriminating benign tremors from Parkinson s disease 18 F-dopa 123 I-FP-CIT 99m Tc-TRODAT Essential tremor Parkinson s disease 158 PS and 27 ET cases: FP-CIT SPECT had a sensitivity 95% and specificity 93% for differentiating between clinically probable PD and ET patients. Benamer 2000 Essential tremor 18 F-dopa Putamen 18 F-dopa Ki essential tremor Ki min -1 0.012 Nor familial sporadic 0.008 PD 0.004 Parkinson s disease 0.000 10

Vascular Parkinsonism Nigral infarct Internal capsule infarct Courtesy of Per Borghammer Glucose metabolism in parkinsonian disorders PD mild PD mod MSA PSP PD MSA CBD Eckert 2007 11

Baseline DAT binding in PPMI series of 400 untreated PD Mean Striatal DAT binding in PD over 4 Years FP-CIT SPECT 2 Contralateral SBR 1 0 2 B y1 y2 y4 Ipsilateral SBR 1 0 B y1 y2 y4 12

Clinical progression of the PPMI cohort PD SWEDD Controls Anti-Parkinson s therapy had been initiated in 36 (24%) Therapy withdrawn in 27 - no evidence of deterioration in 25 Final proportion taking anti-parkinson s therapy 7.3% 13

SWEDD follow-up PPMI cohort 43 of 64 completed 24 mo DAT imaging 5 of 43 now have a visual DAT deficit at follow-up Abnormal SWEDD DTI findings in SWEDDs PPMI cohort Schuff - unpublished 14

18 F-dopa decreases in PD Statistical Parametric Mapping p<0.001 Cingulate Striatum Early hemi-pd Advanced PD Cortical thinning in PD over 18 months Cortical thickness correlates with MOCA scores in PD Cortical thinning progresses faster in PD-MCI than PD Mak 2015 15

Resting network connectivity changes in PD-MCI Decreased dorsal attention network connectivity with frontal and insula regions Increased default mode network connectivity with parieto-occipital regions Baggio 2015 Resting fmri Basal Ganglia network Reduced BG connectivity in PD Szewczyk-Krolikowski 2014 16

Amyloid load in Lewy body disease 11 C-PIB PET volume of distribution Gomperts 2008 17

Microglial activation in Parkinson s disease healthy volunteer Early Parkinsons 18

Inflammation in Parkinson s disease correlates with disability 11 C-PK11195 PET Striatal 11 C-PK11195 uptake correlates with disability (UPDRS III scores - p<.001) Insular 11 C-PK11195 uptake correlates with impaired semantic fluency (p<.01) insula posterior putamen Inflammation in PD + dementia 11 C-PK11195 PET PD PDD PDD>PD 19

Decreased putamen dopamine and increased nigral inflammation in REM Behaviour Disorder Putamen Nigra Stokholm - submitted Conclusions Nigral changes can now be detected with MRI/DTI, TCS, and PET in Parkinson s disease Imaging DA terminal function detects dopamine deficient parkinsonism. Normal DA imaging in uncertain PD has a good prognosis PD is associated with cortical thinning and reduced basal ganglia cortical connectivity The presence of amyloid in PD is associated with rapid cognitive impairment Both DTI and FDG PET sensitively discriminate atypical from typical PD. 20